EU-UK Trade Deal Allows For Mutual Recognition Of GMP Inspections
But No MRA For Batch Testing And Release
Executive Summary
The trade deal agreed by the EU and the UK may have brought some relief to the life sciences sector in that it averts the chaos that would have followed failure to reach a deal, but it contains little that will have a direct impact on the regulation of medicines.
You may also be interested in...
EMA ‘Extremely Collaborative And Well Prepared’ During Review Of Santhera’s DMD Drug Agamree
Santhera Pharmaceuticals’ Agamree is on track to receive pan-EU approval to treat Duchenne muscular dystrophy before the year-end. The company’s CEO and CMO tell the Pink Sheet about its regulatory experience and future market access strategy.
UK BIA To Push For Post-Brexit Regulatory Agreement With EU
There may not be a great deal in the new UK-EU trade and cooperation deal for the life sciences industry but a new working group could act as the forum for constructive discussions on regulatory cooperation.
UK Consumer Health Industry ‘Relieved’ By Post-Brexit Deal
UK consumer health industry association PAGB says it is "relieved" a last minute post-Brexit deal has been struck, which will enable its members to continue to supply OTCs to the EU with limited disruption.